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An exploratory study examining the relationship
between performance status and systemic
inﬂammation frameworks and cytokine proﬁles
in patients with advanced cancer
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Stein Kaasa, MD, PhDd, Paul G. Horgan, FRCS, PhDa, Ørnulf Paulsen, MD, PhDe, Donald C. McMillan, PhDa
Abstract
The role of cytokines in the systemic inﬂammatory response (SIR) is now well established. This is in keeping with the role of the SIR in
tumorigenesis, malignant spread, and the development of cachexia. However, the relationship between performance status/
systemic inﬂammation frameworks and cytokine proﬁles is not clear. The aim of the present study was to examine the relationship
between the Eastern cooperative oncology group performance status/modiﬁed Glasgow prognostic score (ECOG-PS/mGPS) and
cooperative oncology group performance status/neutrophil platelet score (ECOG-PS/NPS) frameworks and their cytokine proﬁle in
patients with advanced cancer.
This was a retrospective interrogation of data already collected as part of a recent clinical trial (NCT00676936). The relationship
between the independent variables (ECOG-PS/mGPS and ECOG-PS/NPS frameworks), and dependent variables (cytokine levels)
was examined using independent Mann–Whitney U and Kruskal Wallis tests where appropriate.
Of the 40 patients included in ﬁnal analysis themajority had evidence of an SIR assessed bymGPS (78%) or NPS (53%). All patients
died on follow-up and the median survival was 91 days (4–933 days). With increasing ECOG-PS there was a higher median value of
Interleukin 6 (IL-6, P= .016) and C-reactive protein (CRP, P< .01) and lower albumin (P< .01) and poorer survival (P< .001). With
increasing mGPS there was a higher median value of IL-6 (P= .016), Macrophage migration inhibitory factor (MIF, P= .010),
erythrocyte sedimentation rate (ESR, P< .01) and poorer survival (P< .01). With increasing NPS there was a higher median value of
TGF-b (P< .001) and C-reactive protein (P= .020) and poor survival (P= .001). When those patients with an ECOG-PS 0/1 and
mGPS0 were compared with those patients with an ECOG-PS 2 and mGPS2 there was a higher median value of IL-6 (P= .017) and
poorer survival (P< .001). When those patients with an ECOG-PS 0/1 and NPS0 were compared with those patients with an ECOG-
PS 2 and NPS1/2 there was a higher median value of IL-6 (P= .002), TGF-b (P< .001) and poorer survival (P< .01).
In patients with advanced cancer IL-6 was associated with the ECOG-PS/mGPS and ECOG-PS/NPS frameworks and survival in
patients with advanced cancer. Therefore, the present work provides supporting evidence that agents targeting IL-6 are worthy of
further exploration.
Abbreviations: TGF-b = transforming growth factor b, BMI = Body Mass Index, CRP = C-reactive protein, ECOG-PS = Eastern
cooperative oncological group performance status, ESR = erythrocyte sedimentation rate, IL = interleukin, LLOQ = lower limit of
quantiﬁcation, MCP-1 = monocyte chemoattractant protein-1, mGPS = modiﬁed Glasgow prognostic score, MIF = macrophage
migration inhibitory factor, MIP-1a = macrophage inﬂammatory protein-1a, NPS = neutrophil platelet score, NSAD = non-steroidal
anti-inﬂammatory drug, OS = overall survival, ra = receptor antagonist, SIR = systemic inﬂammatory response, sTNF-r1 = soluble
tumour necrosis factor receptor-1, TNF-a = tumour necrosis factor a.
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1. Introduction
Cancer is responsible for 7.6 million deaths per annum
globally.[1] Therefore, while a curative intent is the aim of any
surgical or oncological treatment, many patients are likely to
develop disseminated disease requiring systemic anti-cancer
therapy with the aim of improving quality of life, increasing
survival or both. In this setting, measures of Performance Status
(PS), such as the Eastern cooperative oncology group (ECOG)
criteria guide treatment as this has been consistently shown to
predict survival.[2]
Clinical biomarkers of the systemic inﬂammatory response
(SIR) (C-reactive Protein [CRP], albumin, neutrophils, and
platelets) have also become established as having prognostic
accuracy both in operable and in advanced cancer.[3,4] For
example, the modiﬁed Glasgow Prognostic Score (mGPS,
combining CRP, and Albumin) and the neutrophil platelet score
(NPS) have been extensively validated as having prognostic
value.[3–6] Furthermore, the mGPS has been combined with
ECOG performance status in patients with advanced cancer to
reliably stratify quality of life and survival.[2,7,8] These
observations consolidate the role of systemic inﬂammation as
the “seventh hallmark of cancer” and the “tip of the iceberg” in
terms of cancer biology and treatment.[9–11] Indeed, the
activation of the systemic inﬂammatory response has been
strongly implicated in the aggressiveness of the disease and
development of cachexia.[11–13]
Beneath the “tip of the iceberg”, cytokine activity plays an
important part in the development of a systemic inﬂammatory
response and symptoms of advanced disease.[14] In patients with
advanced cancer, pro-inﬂammatory cytokines become predominant
leading to an up-regulation of interleukin (IL) -1, tumour necrosis
factor a (TNF-a), IL-6, IL-8, IL-10, IL-18, transforming growth
factor b (TGF-b) and macrophage migration inhibitory factor
(MIF). However, these cytokines have not been routinely measured
in patients with advanced cancer due to the lack of international
standardisation of analysis and validation of prognostic value. In
contrast, routine measures of the systemic inﬂammatory response,
such as the acute phase proteins CRP and albumin, are well
standardised internationally and, combined in the modiﬁed
Glasgow prognostic score (mGPS), have validated prognostic
value.[3,4] Alternatively, neutrophil counts have been combined
with various other white cell counts, such as lymphocytes and
platelets to improve the prediction of survival.[3,4,15]
To date, the relationship of between cytokines to the ECOG-
PS/mGPS and ECOG-PS/NPS frameworks has not been delin-
eated. Understanding which cytokines are related to performance
status and systemic inﬂammation frameworks and survival may
inform potential treatment in patients with advanced cancer. It is
against this backdrop that we present this retrospective
interrogation of the results of a recent “Corticosteroids for
Cancer Pain” trial [4,5]. This trial examined the relationship
between inﬂammatory biomarkers and symptoms as well as the
effectiveness of steroidal treatment in improving symptoms in
patients with advanced cancer [4]. The present study speciﬁcally
focuses on the relationship between ECOG-PS/mGPS framework
and cytokine proﬁles in patients with advanced cancer.
Therefore, the primary aim of this exploratory study was to
examine the relationship between ECOG-PS/mGPS and ECOG-
PS/NPS frameworks, cytokine proﬁles and survival in patients
with advanced cancer.
2. Patients and methods
This was a retrospective analysis of data already collected as part
of a randomised double-blind placebo control trial examining the
analgesic effects of corticosteroids in patients with advanced
cancer taking opioids.[11,16] The date of inclusion corresponds to
the date of diagnosis with advanced disease. Eligible patients met
the following criteria: >18 years of age, a diagnosis of advanced
cancer where curative treatment was not possible, taking opioids
for moderate or severe cancer pain; pain level of 4 (on a 0 ± 10
Numerical Rating Scale (NRS)) at inclusion; expected survival
>4 weeks. Exclusion criteria included diabetes mellitus, peptic
ulcer disease, and concurrent use of non-steroidal anti-inﬂam-
matory drugs (NSAIDs).[11,16] As part of this trial the following
inﬂammatory biomarkers were collected at trial baseline: CRP,
albumin, neutrophils, platelets, erythrocyte sedimentation rate
(ESR), IL-1b, IL-1ra, TNF-a, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12
(p70), IL-18, interferon-g, TGF-b1, MIF, macrophage inﬂam-
matory protein-1a (MIP-1a), monocyte chemoattractant pro-
tein-1 (MCP-1) and soluble tumour necrosis factor receptor-1
(sTNF-r1). sTNF-r1 was measured as it reﬂects TNF-a-activity,
since TNF-a is among themost unstable cytokines. The analytical
methods are published previously.[11,16] The cytokines were
chosen on the basis of previous research on cancer related
inﬂammation.[17–19] The sera underwent one freeze dry cycle.
Overall survival (OS) was measured until the date of death
from any cause. Ethical approval for the original study was given
by the Regional Committee for Medical Research Ethics Central
Norway (4.2007.846) and the Norwegian Directorate of Health,
and this included further analysis of biobanked data; Clinical trial
information NCT00676936, EudraCT No 2007–005617-19.
Procedures were conducted in accordance with the Declaration
of Helsinki, as revised in 1983.
2.1. Statistical analysis
Data was presented as medians, ranges, frequencies, and
percentages. The mGPS and the neutrophil platelet score
(NPS) were calculated according to methods previously de-
scribed.[6,20] In the present study no formal power calculation
was carried out since, to our knowledge, the relationship between
ECOG-PS/ systemic inﬂammation frameworks and cytokine
proﬁles have not been previously examined. The relationship
between the independent variables (ECOG-PS/mGPS and ECOG-
PS/NPS frameworks), and dependent variables (cytokine levels)
was examined using Independent Mann–WhitneyU and Kruskal
Wallis tests where appropriate. The IL-1ra and IL-6 concen-
trations below the Lower limit of quantiﬁcation (LLOQ) are
given as21.7ng/L and2.33ng/L, respectively. IL-1ra and IL-6
were analysed as continuous and dichotomized variables (IL-1ra:
170ng/L[21] and IL-6: 10ng/L[22]) using the commonest
thresholds reported in the literature. Correlation between
Dolan et al. Medicine (2019) 98:37 Medicine
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different cytokines and markers of the systemic inﬂammatory
response was assessed using Spearman’s rho testing. Given the
explorative nature of this study, a signiﬁcance level of P< .05 was
considered signiﬁcant. The time between the date of inclusion
and the date of death of any cause was used to deﬁne overall
survival (OS). Survival data were analysed using univariate Cox
regression analysis. All statistical analysis was performed using
SPSS version 22.0 (IBM Corp, Armonk, NY).
3. Results
The clinicopathological characteristics of patients are shown in
Table 1. Of the 49 patients previously reported,[11] 9 patients had
incomplete data and therefore 40 patients were included in the
present analysis. The majority of patients were less than 65 years
of age (58%), normal or underweight (73%), had good ECOG-
PS (53%) and were not being treated with ongoing oncological
treatment (73%). The majority of primary cancers were GI or
Lung in origin. Metastatic disease was present in 98% of patients
with the most common sites being the liver and bone. The
majority of patients had evidence of a systemic inﬂammatory
response whether assessed by themGPS (78%) orNPS (53%). All
patients died on follow-up and the median survival was 91 days
(4–933 days).
The relationship between cytokine proﬁles and ECOG-PS,
mGPS and NPS are shown in Table 2a, b, and c, respectively.
With increasing ECOG-PS (Table 2a, poorer performance status)
there was a higher median value of IL-6 (P< .05), ESR (P= .01),
CRP (P< .01), albumin (P< .01), neutrophil count (P< .05) and
poorer survival (P< .001). With increasing mGPS (Table 2b,
increasing systemic inﬂammation) there was a higher median
value of IL-6 (P< .05), MIF (P= .01), ESR (P< .01) and poorer
survival (P< .01). With increasing NPS 2 (Table 2c, increasing
systemic inﬂammation) there was a higher median value of
TGF-b (P< .001) and ESR (P< .05).
The relationship between ECOG-PS and mGPS framework
and the cytokine proﬁle is shown in Table 3. When those patients
with an ECOG-PS 0/1 and mGPS0 were compared with those
patients with an ECOG-PS 2 and mGPS2 there was a higher
median value of IL-6 (P= .017) and poorer survival (P< .001).
The relationship between ECOG-PS and NPS framework and the
cytokine proﬁle is shown in Table 4. When those patients with an
ECOG-PS 0/1 and NPS0 were compared with those patients with
an ECOG-PS 2 and NPS1/2 there was a higher median value of
IL-6 (P= .002) and TGF-b (P< .001) and poorer survival
(P< .01). The majority of IL-1ra and IL-6 and concentrations
were below the limit of detection. There was an increase in IL-6
concentrations between ECOG-PS 0/1 (2.33ng/L) and ECOG_PS
2 (20.4ng/L). In addition, there was an increase in median IL-6
concentrations between mGPS 0 (2.33ng/L) and mGPS 2 (21.1
ng/L). There was also a more progressive increase in IL-6
concentrations between NPS 1 (2.33ng/L), NPS 2 (16.6ng/L) and
NPS 3 (33.6ng/L).
There was no signiﬁcant association between either cancer type
or treatment and IL-6 concentrations (P= .939 and P= .171,
respectively).
4. Discussion
The results of the present study show, for the ﬁrst time, that only
IL-6 was consistently associated with ECOG-PS/mGPS and
ECOG-PS/NPS frameworks in patients with advanced cancer.
These prognostic stratiﬁcation frameworks identify IL-6 as a key
pro-inﬂammatory cytokine in the functional decline and
elaboration of the SIR, important determinants of survival in
patients with cancer and therefore a potential therapeutic target.
Although the present study was carried out in a relatively small
number of patients it does provide pilot data within the context of
an established framework (ECOG-PS/mGPS) that is known to
effectively stratify quality of life and survival in patients with
advanced cancer. For example, the mGPS enables reliable
Table 1
Clinicopathological characteristics of patients within the “Corti-
costeroids and Cancer Pain” trial analysed as part of this study.
Variables n=40 (%)
Age (years)
<65 23 (57.5)
≥65 17 (42.5)
Sex
Female 18 (45.9)
Male 22 (55.0)
BMI
∗
25 29 (76.4)
>25 9 (23.6)
ECOG-PS
0/1 21 (52.5)
2/3 19 (47.5)
mGPS
0: CRP  10 mg/L and albumin  35 g/l 9 (22.5)
1: CRP >10 mg/L 13 (32.5)
2: CRP >10 mg/L and albumin <35 g/L 18 (45.0)
NPS
0: Neutrophils  7.5  109/L and Platelets 400  109/L 19 (47.5)
1: Neutrophils >7.5  109/L or Platelets >400  109/L 14 (35.0)
2: Neutrophils >7.5  109/L and Platelets >400  109/L 7 (17.5)
Cancer type
Breast 2 (5.0)
Prostate 5 (12.5)
GI 9 (22.5)
Lung 9 (22.5)
Gynaecological 8 (20.0)
Other 9 (22.5)
Metastasis site
Liver 14 (35.0)
CNS 2 (5.0)
Bone 14 (35.0)
Lung 6 (15.0)
Other 26 (65.0)
No mets 1 (2.5)
Ongoing oncological treatment
Yes 11 (27.5)
No 29 (72.5)
Treatment randomisation
Steroid (methylprednisolone 16mg BD) 20 (50.0)
Placebo 20 (50.0)
Overall treatment during study
Steroids of any type 31 (77.5)
Placebo 9 (22.5)
Survival
Alive 0 (0)
Dead 40 (100.0)
Survival (days)
Median (range) 91 (4–933)
BMI=Body Mass Index, ECOG-PS=European cooperative oncology group performance status,
mGPS=modiﬁed Glasgow prognostic score, NPS=neutrophil platelet ratio.
∗
2 missing.
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comparison between studies of different tumour types and stages
of disease. Indeed, Kantola, and colleagues in primary operable
CRC (n=148) reported that the mGPS was signiﬁcantly
associated with IL1-ra and IL-6 thus conﬁrming the validity of
the present results.[23,24]
The present results are consistentwith a recent systematic review
by Saligan and co-workers including 6266 patients that showed
serum IL-6 levels were consistently associated with increased
fatigue and poorer performance.[25] In addition, Lippitz and co-
workers, including 11,583 patients reported that serum IL-6 levels
were consistently associatedwith survival in 23 types of cancer.[22]
The average IL-6 threshold was approximately 10 ng/l and this is
above the top of the recognised reference range (in the present
analysis<2.33 ng/l). In the present study when this threshold was
applied IL-6 was signiﬁcantly associated with ECOG-PS, mGPS,
and survival. Therefore, the results of the present study are
consistent with the literature and deﬁne IL-6 as a tumour
type independent factor for the progressive functional decline
(ECOG-PS), elaboration of the systemic inﬂammatory response
(mGPS) and poorer survival in patients with advanced cancer.
It has long been recognised that interleukin-6 was associated
with pain,[26] weight loss,[27] and inﬂammatory responses in
patients with cancer.[28,29] However, it is only in recent years that
the systemic inﬂammatory response, in particular as measured by
the mGPS, has become central to the symptoms associated with
advanced cancer[2,13] and there has been a repertoire of agents
targeting IL-6, directly or indirectly, to clinically test these
associations in a robust manner.
Table 2
a–c: The relationship between ECOG-PS (2a), mGPS (2b), and NPS (2c) and the cytokine proﬁle.
Table 2a ECOG-PS Median (range)
Cytokines Normal reference range 0/1 n=21 ≥2 n=19 P value
IL-1 ra <21.7 ng/L 21.7 (21.7–1641) 21.7 (21.7–4360) .357
IL-6 <2.33 ng/L 2.33 (2.33–58.7) 20.4 (2.33–97.3) .016
IL-18 <1.1 ng/L 99.5 (50.1–257) 107 (26.5–4588) .466
MCP-1 <1.5 ng/L 61.4 (30.4–188) 81.0 (19.6–1235) .654
MIF <4.8 ng/L 142 (45.1–722) 135 (40.9–745) .520
sTNF-r1 <27.1 ng/L 10665 (813–24174) 12058 (3266–25934) .143
TGF-b <1.2 ng/L 45124 (21856–66224) 50784 (26249–103280) .330
ESR M: 0–22 mm/h F: 0.29 mm/h 37 (3–136) 67 (18–109) .030
CRP <3 mg/dl 20 (0.5–138) 64 (33–305) .002
Albumin 35–50 g/L 39 (28–48) 31 (17–44) .001
Neutrophil 2–7.5  109/L 3.7 (1.2–11) 6.4 (1–17.3) .040
Platelet 150–400  109/L 316 (80–592) 422 (115–689) .209
Survival (days) 200 (28–933) 50 (4–189) <.001
Table 2b mGPS median (range)
Cytokines Normal reference ranges 0 n=9 1 n=13 2 n=18 P value
IL-1 ra <21.7 ng/L 21.7 (21.7–179) 21.7 (21.7–1641) 21.7 (21.7–4360) .633
IL-6 <2.33 ng/L 2.33 (2.33–39.9) 2.33 (2.33–58.7) 21.1 (2.33–118) .016
IL-18 <1.1 ng/L 84.6 (57.5–257) 107 (52.4–226) 103 (26.5–4588) .523
MCP-1 <1.5 ng/L 63.1 (43.7–164) 90.0 (30.4–188) 61.2 (19.6–1235) .254
MIF <4.8 ng/L 85.4 (45.1–186) 329 (79.5–745) 127 (40.9–1348) .010
TGF-b <27.1 ng/L 43279 (27144–57458) 47923 (21856–66224) 48293 (23402–103280) .430
sTNF-r1 <1.2 ng/L 8459 (813–15257) 11734 (3723–24174) 10953 (3266–33794) .359
ESR M: 0–22 mm/h F: 0.29 mm/h 16 (3–87) 40 (11–95) 72 (18–136) .002
Neutrophil 2–7.5  109/L 3.5 (1.2–9.5) 5.7 (2.2–11) 6.45 (1–17.4) .060
Platelet 150–400  109/L 316 (156–353) 400 (80–592) 406 (72–728) .516
Survival (days) 511 (21–933) 117 (28–406) 51 (4–474) .003
Table 2c NPS median (range)
Cytokines Normal reference ranges 0 n=19 1 n=14 2 n=7 P value
IL-1 ra <21.7 ng/L 21.7 (21.7–1640) 21.7 (21.7–519) 21.7 (21.7–4360) .483
IL-6 <2.33 ng/L 2.33 (2.33–58.7) 16.6 (2.33–105) 33.6 (2.33–118) .052
IL-18 <1.1 ng/L 95.0 (52.4–257) 107 (26.5–191) 153 (74.2–4588) .247
MCP-1 <1.5 ng/L 59.3 (19.6–164) 70.1 (36.5–188) 81 (36.4–1235) .863
MIF <4.8 ng/L 126 (40.9–722) 126 (73.6–745) 338 (128–1348) .088
TGF-b <27.1 ng/L 37694 (21856–50694) 51113 (23402–103280) 61194 (40449–66224) <.001
sTNF-r1 <1.2 ng/L 9267 (813–25934) 11286 (3723–33794) 15257 (8459–22060) .170
ESR M: 0–22 mm/h F: 0.29mm/h 37 (3–102) 53.5 (6–136) 72 (15–109) .161
CRP <3 mg/dl 33 (0.5–138) 47 (3.8–167) 138 (1.9–305) .020
Albumin 35–50 g/L 36 (25–45) 33 (24–48) 31 (14–40) .173
Survival (days) 132 (14–933) 77 (38–406) 37 (4–474) .154
CRP=C-reactive protein, ESR= erythrocyte sedimentation rate, ESR= erythrocyte sedimentation rate, IL= interleukin, MCP-1=monocyte chemoattractant protein-1, mGPS=modiﬁed Glasgow prognostic
score, MIF=macrophage migration inhibitory factor, MIP-1a=macrophage inﬂammatory protein-1a, NPS=neutrophil platelet score, NSAD=non-steroidal anti-inﬂammatory drug, ra= receptor antagonist,
sTNF-r1= soluble tumour necrosis factor receptor-1, TGF-b= transforming growth factor b, TNF-a= tumour necrosis factor a.
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Therapeutic strategies have been suggested to target IL-6
directly, upstream or downstream. Currently inhibitors that
target IL-6 directly, IL-6R or selectively block IL-6 trans-
signalling are in clinical trial development and may be useful in
managing immune mediated adverse events associated with PD-1
inhibitors.[23] Furthermore, Clazakizumab, which targets IL-6,
has also been examined in phase II trials and showed attenuation
of muscle loss and improvements in anaemia.[30]
In terms of upstream signalling IL-1 plays a signiﬁcant role.[31]
Both IL-1a and IL-1b have pro-inﬂammatory properties through
the IL-1R1 receptor. IL-1a shows a strong association with
monocytes and lymphocytes while IL-1b shows as similar
association with neutrophils.[32] These results are consistent
with the recent report that targeting IL-1a was associated with
beneﬁcial effects on muscle mass and quality of life.[33] In the
present study it was of interest that of the cytokines measured
only IL-1ra was signiﬁcantly associated with IL-6 (rs 0.537,
P< .001), CRP (rs 0.320, P< .05) and neutrophil count (rs 0.353,
P< .05) (results not tabulated). There are also a number of
approaches to down regulate IL-1 signalling that look promising
in patients with advanced cancer and worthy of clinical
investigation.[34]
In terms of downstream signalling IL-6 activates the JAK/
STAT3 pathway.[35] Ruxolitinib is a potent JAK1/JAK2 inhibitor
which is effective in treating patients with myeloﬁbrosis,
myeloproliferative neoplasm associated with cachexia, weight
loss, elevated proinﬂammatory cytokines, and dysregulated
JAK/STAT signalling.[36] Ruxolitinib acts by reducing the
proinﬂammatory cytokine levels which leads to improved
myeloﬁbrosis-related symptoms, weight gain, and improved
overall survival (OS).[36]
Therefore, although there are agents that can target IL-6
upstream and downstream, such complexity, many studies
carried out have been pre-clinical and the data makes it difﬁcult
to predict the likely beneﬁts of any particular agent in patients
with advanced cancer. In this context, the results of the present
study would suggest that such agents may be useful in patients
with poor performance status and elevated systemic inﬂamma-
tory response, that is, ECOG-PS 2 andmGPS 2 for moderation of
symptoms.
Although assays have been available for the measurement of
IL-6 in the plasma for approximately 30 years there remain a
number of obstacles to be overcome before IL-6 will become a
routinely available in clinical practice. Until such time the ECOG-
PS/mGPS framework will continue to offer reliable risk
stratiﬁcation for patients with advanced cancer. Indeed, given
the extensively validated prognostic value of the ECOG-PS/
mGPS framework, it is clear that of the cytokines measured, IL-6
may represent a potentially useful therapeutic target to improve
patient status in the context of this framework. Furthermore, as
clinical trials continue IL-1 and IL-6 or their surrogate markers
could be used to assess the effectiveness of an intervention to
dampen cancer associated inﬂammation. This is particularly true
for CRP as a singular marker and the mGPS as a combined
prognostic score.[3,4]
The present study had some limitations. There were relatively
small numbers of patient observations in some of the subgroup
analysis. This may explain why markers previously associated
with cancer inﬂammation in the literature, such as TGF-b and
MIF approached but did not reach signiﬁcance. A large number
of cytokines were analysed as part of this study however these
were all previously associated with cancer related inﬂammation.
Table 4
The relationship between combined ECOG 0/1 and NPS 0 and combined ECOG 2 and NPS 1/2 and cytokine levels.
n=23 LLOQ: ECOG 0/1 and NPS 0 (n=13) Median (range) ECOG 2 and NPS 1/2 (n=10) Median (range) P value
IL-1 ra <21.7 pg/ml 21.7 (21.7–1641) 21.7 (21.7–4360) .376
IL-6 <2.33 pg/ml 2.33 (2.33–58.7) 26.7 (2.33–97.3) .002
IL-18 <1.1 pg/ml 99.2 (52.4–257) 112 (26.5–4588) .446
MCP-1 <1.5 pg/ml 78.1 (30.4–164) 82.3 (42.2–1235) .738
MIF <4.8 pg/ml 142 (45.1–722) 194 (91.2–745) .343
sTNF-r1 <27.1 pg/ml 10893 (813–18310) 14400 (4806–22060) .057
TGF-b <1.2 pg/ml 37226 (21856–50694) 52039 (40449–103280) <.001
Survival (days) 296 (28–933) 60 (32–115) .005
TGF-b= transforming growth factor b, ECOG-PS=European cooperative oncology group performance status, IL= interleukin, MCP-1=monocyte chemoattractant protein-1, MIF=macrophage migration inhibitory
factor, MIP-1a=macrophage inﬂammatory protein-1a, NPS=neutrophil platelet score, ra= receptor antagonist, sTNF-r1= soluble tumour necrosis factor receptor-1, TNF-a= tumour necrosis factor a.
Table 3
The relationship between combined ECOG-PS 0/1 and mGPS 0 and combined ECOG-PS 2 and mGPS 2 and cytokine levels.
n=19 LLOQ: ECOG-PS 0/1 and mGPS 0 (n=7) Median (range) ECOG-PS 2 and mGPS 2 (n=12) Median (range) P value
IL-1 ra <21.7 ng/L 21.7 (21.7–179) 21.7 (21.7–4360) .711
IL-6 <2.33 ng/L 2.33 (2.33–2.33) 15.9 (2.33–97.3) .017
IL-18 <1.1 ng/L 84.6 (57.5–257) 100 (26.5–4588) .711
MCP-1 <1.5 ng/L 59.3 (43.7–164) 67.6 (19.6–1235) .902
MIF <4.8 ng/L 85.4 (45.1–186) 107 (40.9–635) .432
sTNF-r1 <27.1 ng/L 7618 (813–14901) 11064 (3266–25934) .167
TGF-b <1.2 ng/L 37226 (27144–49734) 48293 (26249–103280) .068
Survival (days) 638 (92–933) 60 (14–189) <.001
ECOG-PS=European cooperative oncology group performance status, IL= interleukin, MCP-1=monocyte chemoattractant protein-1, mGPS=modiﬁed Glasgow prognostic score, MIF=macrophage migration
inhibitory factor, MIP-1a=macrophage inﬂammatory protein-1a, ra= receptor antagonist, sTNF-r1= soluble tumour necrosis factor receptor-1, TGF-b= transforming growth factor b, TNF-a= tumour
necrosis factor a.
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Given the exploratory nature of this study and the small number
of patients, no correction for multiple testing was performed.
Also, the present results are a retrospective analysis of trial data
obtained from a study examining the relationship between
cytokine concentrations and symptoms in patients with advanced
cancer.[11] As a result, prospective conﬁrmation of the results
obtained and measurement of key cytokines would be important
in future studies.
In summary, the present work provides supporting evidence
that agents targetting IL-6 are worthy of further exploration.
However, it will be important to include some stratiﬁcation for
the systemic inﬂammatory response, for example, the ECOG-PS/
mGPS framework, into trial designs, to enable the effect of these
agents to be optimally assessed. Such an approach has been
advocated recently[37] and demonstrated as being efﬁcacious in
similar settings.[36]
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